218
Participants
Start Date
December 31, 2014
Primary Completion Date
December 31, 2015
Study Completion Date
December 31, 2015
Omalizumab
Omalizumab was supplied as a lyophilized, sterile powder in a single-use vial.
Placebo
Placebo was supplied as a lyophilized, sterile powder in a single-use vial without study drug.
Novartis Investigative Site, Seongnam-si
Novartis Investigative Site, Toyoake
Novartis Investigative Site, Hiroshima
Novartis Investigative Site, Kobe
Novartis Investigative Site, Nishinomiya
Novartis Investigative Site, Hitachi
Novartis Investigative Site, Takamatsu
Novartis Investigative Site, Kawasaki
Novartis Investigative Site, Yokohama
Novartis Investigative Site, Yokohama
Novartis Investigative Site, Yokohama
Novartis Investigative Site, Yokosuka
Novartis Investigative Site, Kamimashi-gun
Novartis Investigative Site, Nagano
Novartis Investigative Site, Osaka
Novartis Investigative Site, Sakai
Novartis Investigative Site, Saitama
Novartis Investigative Site, Izumo
Novartis Investigative Site, Kodaira
Novartis Investigative Site, Machida
Novartis Investigative Site, Meguro-ku
Novartis Investigative Site, Minato-ku
Novartis Investigative Site, Ōta-ku
Novartis Investigative Site, Shinagawa-ku
Novartis Investigative Site, Shinjuku-ku
Novartis Investigative Site, Kofu
Novartis Investigative Site, Wŏnju
Novartis Investigative Site, Hwaseong-si
Novartis Investigative Site, Suwon
Novartis Investigative Site, Seoul
Novartis Investigative Site, Seoul
Novartis Investigative Site, Seoul
Novartis Investigative Site, Seoul
Novartis Investigative Site, Busan
Novartis Investigative Site, Daegu
Novartis Investigative Site, Gwangju
Novartis Investigative Site, Incheon
Novartis Investigative Site, Seoul
Novartis Investigative Site, Seoul
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY